Tilarin in combination with astemizole

Donald A. Bukstein, Robert M. Biondi, Malcolm M. Blumenthal, Robert J. Dockhorn, Warren V. Filley, Jordan Fink, Stanley Goldstein, David F. Graft, S. Roger Hirsch, Thaddeus H. Joos, Julian Melamed, Michael S. Rowe, Robert G. Townley

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This multicentre double-blind, placebo controlled study had a practical objective, based on the expectation that many patients with seasonal allergic rhinitis will be prescribed oral antihistamine monotherapy by their primary care physician, whereas allergy specialists are more likely to prescribe combination therapy including antiinflammatories. The specific question was, 'Will the addition of nedocromil sodium 1% nasal spray to astemizole tablets improve control of symptoms of seasonal allergic rhinitis induced by ragweed pollen, as compared to astemizole therapy alone?'. Following a one-week baseline, planned to coincide with the start of the local ragweed pollen season, patients (aged 12-64) were randomly assigned to four weeks' double-blind test treatment with either nedocromil sodium 1% nasal spray four times daily (QID) + astemizole (n = 146) or placebo nasal spray + astemizole (n = 148) or double-dummy (nasal spray + capsules) placebo (n = 71). Patient diary cards were kept throughout the five weeks, and clinic visits were made before and after baseline and after one and four weeks' treatment. During the 10-day peak pollen period, the diary card rhinitis symptom summary score (0-4 severity scale) was significantly reduced in patients receiving either astemizole alone (p <0.001) or the combination therapy (p <0.001) as compared with placebo. Direct comparison of the active treatments further showed that symptoms were significantly less severe (p <0.01) with the combined therapy than with astemizole alone, and this despite significantly greater reliance on permitted rescue medications (p <0.05 for pseudoephedrine usage) in the astemizole group. Clinical assessments of rhinitis made during the peak pollen visit, after the first week of test treatment, were also significantly (p <0.05-p <0.01) in favour of combined therapy with nedocromil sodium 1% nasal spray + astemizole rather than astemizole alone, and at the same time this preference was confirmed by physician (p = 0.011) and patient (p = 0.003) opinions of symptom control. In conclusion, this antiinflammatory + antihistamine treatment proved superior to antihistamine alone for effective management of allergic rhinitis. The combined therapy worked quickly and was well-tolerated, with no serious adverse events or untoward effects on blood or urine variables.

Original languageEnglish
Pages (from-to)20-27
Number of pages8
JournalAllergy: European Journal of Allergy and Clinical Immunology, Supplement
Volume51
Issue number28
StatePublished - 1996
Externally publishedYes

Fingerprint

Astemizole
Nasal Sprays
Nedocromil
Histamine Antagonists
Placebos
Therapeutics
Seasonal Allergic Rhinitis
Rhinitis
Pollen
Anti-Inflammatory Agents
Pseudoephedrine
Primary Care Physicians
Ambulatory Care
Tablets
Capsules

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Bukstein, D. A., Biondi, R. M., Blumenthal, M. M., Dockhorn, R. J., Filley, W. V., Fink, J., ... Townley, R. G. (1996). Tilarin in combination with astemizole. Allergy: European Journal of Allergy and Clinical Immunology, Supplement, 51(28), 20-27.

Tilarin in combination with astemizole. / Bukstein, Donald A.; Biondi, Robert M.; Blumenthal, Malcolm M.; Dockhorn, Robert J.; Filley, Warren V.; Fink, Jordan; Goldstein, Stanley; Graft, David F.; Hirsch, S. Roger; Joos, Thaddeus H.; Melamed, Julian; Rowe, Michael S.; Townley, Robert G.

In: Allergy: European Journal of Allergy and Clinical Immunology, Supplement, Vol. 51, No. 28, 1996, p. 20-27.

Research output: Contribution to journalArticle

Bukstein, DA, Biondi, RM, Blumenthal, MM, Dockhorn, RJ, Filley, WV, Fink, J, Goldstein, S, Graft, DF, Hirsch, SR, Joos, TH, Melamed, J, Rowe, MS & Townley, RG 1996, 'Tilarin in combination with astemizole', Allergy: European Journal of Allergy and Clinical Immunology, Supplement, vol. 51, no. 28, pp. 20-27.
Bukstein DA, Biondi RM, Blumenthal MM, Dockhorn RJ, Filley WV, Fink J et al. Tilarin in combination with astemizole. Allergy: European Journal of Allergy and Clinical Immunology, Supplement. 1996;51(28):20-27.
Bukstein, Donald A. ; Biondi, Robert M. ; Blumenthal, Malcolm M. ; Dockhorn, Robert J. ; Filley, Warren V. ; Fink, Jordan ; Goldstein, Stanley ; Graft, David F. ; Hirsch, S. Roger ; Joos, Thaddeus H. ; Melamed, Julian ; Rowe, Michael S. ; Townley, Robert G. / Tilarin in combination with astemizole. In: Allergy: European Journal of Allergy and Clinical Immunology, Supplement. 1996 ; Vol. 51, No. 28. pp. 20-27.
@article{1d9427c2c4af44b8a420279f2d4c8784,
title = "Tilarin in combination with astemizole",
abstract = "This multicentre double-blind, placebo controlled study had a practical objective, based on the expectation that many patients with seasonal allergic rhinitis will be prescribed oral antihistamine monotherapy by their primary care physician, whereas allergy specialists are more likely to prescribe combination therapy including antiinflammatories. The specific question was, 'Will the addition of nedocromil sodium 1{\%} nasal spray to astemizole tablets improve control of symptoms of seasonal allergic rhinitis induced by ragweed pollen, as compared to astemizole therapy alone?'. Following a one-week baseline, planned to coincide with the start of the local ragweed pollen season, patients (aged 12-64) were randomly assigned to four weeks' double-blind test treatment with either nedocromil sodium 1{\%} nasal spray four times daily (QID) + astemizole (n = 146) or placebo nasal spray + astemizole (n = 148) or double-dummy (nasal spray + capsules) placebo (n = 71). Patient diary cards were kept throughout the five weeks, and clinic visits were made before and after baseline and after one and four weeks' treatment. During the 10-day peak pollen period, the diary card rhinitis symptom summary score (0-4 severity scale) was significantly reduced in patients receiving either astemizole alone (p <0.001) or the combination therapy (p <0.001) as compared with placebo. Direct comparison of the active treatments further showed that symptoms were significantly less severe (p <0.01) with the combined therapy than with astemizole alone, and this despite significantly greater reliance on permitted rescue medications (p <0.05 for pseudoephedrine usage) in the astemizole group. Clinical assessments of rhinitis made during the peak pollen visit, after the first week of test treatment, were also significantly (p <0.05-p <0.01) in favour of combined therapy with nedocromil sodium 1{\%} nasal spray + astemizole rather than astemizole alone, and at the same time this preference was confirmed by physician (p = 0.011) and patient (p = 0.003) opinions of symptom control. In conclusion, this antiinflammatory + antihistamine treatment proved superior to antihistamine alone for effective management of allergic rhinitis. The combined therapy worked quickly and was well-tolerated, with no serious adverse events or untoward effects on blood or urine variables.",
author = "Bukstein, {Donald A.} and Biondi, {Robert M.} and Blumenthal, {Malcolm M.} and Dockhorn, {Robert J.} and Filley, {Warren V.} and Jordan Fink and Stanley Goldstein and Graft, {David F.} and Hirsch, {S. Roger} and Joos, {Thaddeus H.} and Julian Melamed and Rowe, {Michael S.} and Townley, {Robert G.}",
year = "1996",
language = "English",
volume = "51",
pages = "20--27",
journal = "Allergy: European Journal of Allergy and Clinical Immunology, Supplement",
issn = "0108-1675",
publisher = "Wiley-Blackwell",
number = "28",

}

TY - JOUR

T1 - Tilarin in combination with astemizole

AU - Bukstein, Donald A.

AU - Biondi, Robert M.

AU - Blumenthal, Malcolm M.

AU - Dockhorn, Robert J.

AU - Filley, Warren V.

AU - Fink, Jordan

AU - Goldstein, Stanley

AU - Graft, David F.

AU - Hirsch, S. Roger

AU - Joos, Thaddeus H.

AU - Melamed, Julian

AU - Rowe, Michael S.

AU - Townley, Robert G.

PY - 1996

Y1 - 1996

N2 - This multicentre double-blind, placebo controlled study had a practical objective, based on the expectation that many patients with seasonal allergic rhinitis will be prescribed oral antihistamine monotherapy by their primary care physician, whereas allergy specialists are more likely to prescribe combination therapy including antiinflammatories. The specific question was, 'Will the addition of nedocromil sodium 1% nasal spray to astemizole tablets improve control of symptoms of seasonal allergic rhinitis induced by ragweed pollen, as compared to astemizole therapy alone?'. Following a one-week baseline, planned to coincide with the start of the local ragweed pollen season, patients (aged 12-64) were randomly assigned to four weeks' double-blind test treatment with either nedocromil sodium 1% nasal spray four times daily (QID) + astemizole (n = 146) or placebo nasal spray + astemizole (n = 148) or double-dummy (nasal spray + capsules) placebo (n = 71). Patient diary cards were kept throughout the five weeks, and clinic visits were made before and after baseline and after one and four weeks' treatment. During the 10-day peak pollen period, the diary card rhinitis symptom summary score (0-4 severity scale) was significantly reduced in patients receiving either astemizole alone (p <0.001) or the combination therapy (p <0.001) as compared with placebo. Direct comparison of the active treatments further showed that symptoms were significantly less severe (p <0.01) with the combined therapy than with astemizole alone, and this despite significantly greater reliance on permitted rescue medications (p <0.05 for pseudoephedrine usage) in the astemizole group. Clinical assessments of rhinitis made during the peak pollen visit, after the first week of test treatment, were also significantly (p <0.05-p <0.01) in favour of combined therapy with nedocromil sodium 1% nasal spray + astemizole rather than astemizole alone, and at the same time this preference was confirmed by physician (p = 0.011) and patient (p = 0.003) opinions of symptom control. In conclusion, this antiinflammatory + antihistamine treatment proved superior to antihistamine alone for effective management of allergic rhinitis. The combined therapy worked quickly and was well-tolerated, with no serious adverse events or untoward effects on blood or urine variables.

AB - This multicentre double-blind, placebo controlled study had a practical objective, based on the expectation that many patients with seasonal allergic rhinitis will be prescribed oral antihistamine monotherapy by their primary care physician, whereas allergy specialists are more likely to prescribe combination therapy including antiinflammatories. The specific question was, 'Will the addition of nedocromil sodium 1% nasal spray to astemizole tablets improve control of symptoms of seasonal allergic rhinitis induced by ragweed pollen, as compared to astemizole therapy alone?'. Following a one-week baseline, planned to coincide with the start of the local ragweed pollen season, patients (aged 12-64) were randomly assigned to four weeks' double-blind test treatment with either nedocromil sodium 1% nasal spray four times daily (QID) + astemizole (n = 146) or placebo nasal spray + astemizole (n = 148) or double-dummy (nasal spray + capsules) placebo (n = 71). Patient diary cards were kept throughout the five weeks, and clinic visits were made before and after baseline and after one and four weeks' treatment. During the 10-day peak pollen period, the diary card rhinitis symptom summary score (0-4 severity scale) was significantly reduced in patients receiving either astemizole alone (p <0.001) or the combination therapy (p <0.001) as compared with placebo. Direct comparison of the active treatments further showed that symptoms were significantly less severe (p <0.01) with the combined therapy than with astemizole alone, and this despite significantly greater reliance on permitted rescue medications (p <0.05 for pseudoephedrine usage) in the astemizole group. Clinical assessments of rhinitis made during the peak pollen visit, after the first week of test treatment, were also significantly (p <0.05-p <0.01) in favour of combined therapy with nedocromil sodium 1% nasal spray + astemizole rather than astemizole alone, and at the same time this preference was confirmed by physician (p = 0.011) and patient (p = 0.003) opinions of symptom control. In conclusion, this antiinflammatory + antihistamine treatment proved superior to antihistamine alone for effective management of allergic rhinitis. The combined therapy worked quickly and was well-tolerated, with no serious adverse events or untoward effects on blood or urine variables.

UR - http://www.scopus.com/inward/record.url?scp=9044236157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044236157&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 20

EP - 27

JO - Allergy: European Journal of Allergy and Clinical Immunology, Supplement

JF - Allergy: European Journal of Allergy and Clinical Immunology, Supplement

SN - 0108-1675

IS - 28

ER -